Trial · NCT06898047
Consistency of Response With Rimegepant in Acute Treatment of Migraine
NCT06898047, Active not recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Consistency of Response With Rimegepant in Acute Treatment of Migraine. Trials, record NCT06898047. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06898047
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Consistency of Response With Rimegepant in Acute Treatment of Migraine
- NCT number
- NCT06898047
- Status
- Active not recruiting
- Enrollment
- 250 participants, estimated
- Lead sponsor
- Pfizer
- Conditions
- Migraine
- Interventions
- Rimegepant for acute migraine treatment
- First posted
- 2025-03-27
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Meaninful Pain Relief (MPR) post-dosing | Daily (within 24hs post dose) | Proportion of rimegepant-treated attacks with reported MPR: within 1 hour post dose; 1-2 hours post dose; Over 2 hours up to 4 hours post dose; More than 4 hours post dose; who have not achieved MPR and took the medication more than 2 hours before completing the survey; who have not achieved MPR and took the medication less than 2 hours before completing the survey |
| Secondary | Time to improvement in non-pain symptoms post-dosing | Daily (within 24hs post dose) | Proportion of rimegepant-treated attacks with reported improvement in any non-pain symptoms: within 1 hour post dose; 1-2 hours post dose; Over 2 hours up to 4 hours post dose; More than 4 hours post dose; who have not had a meaninful improvement and took the medication more than 2 hours before completing the survey; who have not had a meaninful improvement and took the medication less than 2 hours before completing the survey. |
| Secondary | Acute migraine treatment optmization | 12 weeks follow up | Proportion of participants who reported treatment optimization using mTOQ6 questionnaire. Treatment optimization is categorized into: very poor treatment optimization, poor treatment optimization, moderate treatment optimization, maximum treatment optimization |
| Secondary | Acute migraine treatment optmization | 12 weeks follow up | Treatment satisfaction assessed using TSQM-II questionnaire. Domain scores (0-100) is presented for the following domains: effectiveness, Side effects, Convenience, and global satisfaction. Higher scores indicate greater satisfaction. Scores are reported separately for each domain. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06898047
GET https://conductscience.org/api/trials/v1/NCT06898047/registered